Septerna, Inc. (SEPN) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $26.51: Leverage penalty (D/E 6.1): -1.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule... Read more
Sell if holding. Multiple concerning factors at $26.51: Leverage penalty (D/E 6.1): -1.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0). Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Score 5.1/10, high confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Septerna, Inc.
Latest news
- HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target — benzinga May 13, 2026 positive
- Septerna Q1 EPS $(0.19) Beats $(0.42) Estimate, Sales $26.523M Beat $16.938M Estimate — benzinga May 11, 2026 positive
- Septerna Doses First Participants In Phase 1 Trial Of SEP-479 For Hypoparathyroidism — benzinga Apr 13, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $26.51: Leverage penalty (D/E 6.1): -1.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0). Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Prior stop was $24.65. Score 5.1/10, high confidence.
Take-profit target: $38.50 (+45.2% upside). Prior stop was $24.65. Stop-loss: $24.65.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0); Leverage penalty (D/E 6.1): -1.5; Consecutive earnings misses (3).
Septerna, Inc. trades at a P/E of N/A (forward -10.6). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover SEPN with a consensus score of 4.1/5. Average price target: $44.
What does Septerna, Inc. do?Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral...
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.